WHO WE ARE IISG is a Phase 2 clinical-stage biotechnology company
At IISG, we are developing new cancer drugs to specifically target tumors, and with minimal side effects for patients.
PRL3 is an intracellular tumor-specific antigen overexpressed in about 80.6% of cancer patients. Conventionally, chemotherapy is used to target molecules that reside in cancer cells, such as PRL3 intracellular oncoprotein. Antibody drugs are not used to target intracellular oncotargets due to their inability to cross cell membranes. However, we discovered that PRL3 intracellular oncotarget could be externalised as an ‘extracellular’ antigen on the surface of cancer cells and to be targeted by antibodies to trigger the host’s immune system via ADCC/ADCP (Thura et al., Nature Communications 2019). This discovery opens a new avenue for cancer immunotherapy against a spectrum of intracellular oncotargets.
PRL3-zumab is our first Flagship antibody drug and is representative of an innovative and disruptive approach in a new era of cancer immunotherapy. We anticipate that PRL3-zumab will bring clinical benefits to majority of PRL3 positive cancer patients.ABOUT US
PRL3 is an intracellular protein (inside cell) overexpressed in many tumors and has been reported globally by many research laboratories. Since PRL3 is specifically overexpressed in tumors but undetectable in most normal tissues, we anticipate that PRL3 is an excellent tumor specific antigen for cancer therapy. Traditionally, intracellular oncoproteins (such as PRL3) are targeted by small chemical inhibitors (chemotherapy), mainly because intracellular compartments are presumed to be inaccessible to large antibody drugs. However, as compared to chemotherapy, antibody therapy is more target-specific and has less off-target side effects.
In 2016, PRL3-zumab was approved for Phase I clinical trial by Health Sciences Authority (HSA), Singapore. After the successful safety trial, Phase II clinical trial for drug efficacy was approved by HSA in 2019.
In 2020, Phase II clinical trials have been approved by the Food and Drug Administration (FDA) in the United States and by the National Medical Products Administration (NMPA) in China to conduct multi-center clinical trials in USA and China respectively.
IISG is spearheading a new era of Cancer Immunotherapy that specifically targets tumors, yet keeping normal organs unharmed, thus greatly reducing side-effects. Today, IISG has developed a strong portfolio of next-generation antibody therapies to treat a spectrum of cancer indications via targeting multiple intracellular oncoproteins.
IISG is established with the aim to develop more effective cancer immunotherapies with minimal side effects as compared to traditional cancer drugs.
We are committed to improve the lives of cancer patients across the world. Through the development of our high affinity monoclonal antibodies, we strive to provide patients with more effective, safer and long-lasting treatment options for a broad range of cancers.READ MORE